FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022972276> ?p ?o ?g. }

• W2022972276 endingPage "2337" @default.
• W2022972276 startingPage "2337" @default.
• W2022972276 abstract "Abstract Selective RAF inhibitors have a significant role in the treatment of patients with metastatic melanoma whose tumors express BRAFV600E with the majority of patients experiencing significant tumor regression. However in patients with colorectal cancer (CRC) whose tumors express BRAFV600E, response-rates appear to be much lower, with only a few patients reported to experience a partial tumor response to vemurafenib (Kopetz et al., 2010) or the combination of dabrafenib plus trametinib (Corcoran et al., 2012). LGX818 is a highly potent RAF inhibitor with selective anti-proliferative activity in cells expressing BRAFV600E. A distinguishing feature of LGX818 is its very long dissociation half-life from BRAFV600E which leads to strong and sustained target inhibition even following drug wash-out. In addition, LGX818 has a very wide therapeutic index, with tumor regression observed at doses as low as 3 mg/kg bid and excellent tolerability up to 300 mg/kg bid in melanoma xenograft models. In the CRC cell line Colo205 (BRAFV600E), LGX818 inhibits proliferation with an EC50 = 0.005 μM and in vivo leads to significant tumor regression at doses as low as 20 mg/kg. However, other BRAFV600E CRC cell lines do not appear to be as sensitive (EC50 = 0.018 to &gt;2.7 μM) and this intrinsic resistance translates in vivo in xenograft models generated from these cell lines. Based on clinical and preclinical data, it is clear that combination strategies will be required if RAF inhibitors are going to play a significant role in the treatment of CRC. Recent publications have implicated feedback-mediated activation of EGFR in BRAFV600E CRC cells treated with RAF and MEK inhibitors and this led us to test combinations of LGX818 with anti-EGFR therapies such as cetuximab and erlotinib. In vitro and in vivo studies indicated that the combination of LGX818 with cetuximab or erlotinib can be highly synergistic, leading to enhanced cell killing. In vivo the combination of LGX818 + cetuximab led to complete inhibition of tumor growth at doses where no single-agent activity was observed. Since PIK3CA mutations often co-occur with BRAFV600E in CRC tumors, we also tested the alpha-selective PI3K inhibitor BYL719 in combination with LGX818 and cetuximab as a triple combination. In vitro, this triple combination produced synergistic anti-proliferative effects and in vivo resulted in tumor regression. These preclinical data led to the initiation of an ongoing Phase I/II trial to evaluate the triple combination of LGX818, cetuximab and BYL719 in BRAFV600E CRC. Based on the preclinical results described above it is anticipated that the combination of a RAF inhibitor with anti-EGFR therapy and a PI3K inhibitor will have superior efficacy to single-agent RAF inhibitor in BRAFV600E CRC. Citation Format: Giordano Caponigro, Z A. Cao, Xiaobin Zhang, Hui Q. Wang, Christine M. Fritsch, Darrin D. Stuart. Efficacy of the RAF/PI3Kα/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600E colorectal tumor models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2337. doi:10.1158/1538-7445.AM2013-2337" @default.
• W2022972276 created "2016-06-24" @default.
• W2022972276 creator A5022308157 @default.
• W2022972276 creator A5025118565 @default.
• W2022972276 creator A5038165954 @default.
• W2022972276 creator A5043091366 @default.
• W2022972276 creator A5049772515 @default.
• W2022972276 creator A5082210211 @default.
• W2022972276 date "2013-04-01" @default.
• W2022972276 modified "2023-09-28" @default.
• W2022972276 title "Abstract 2337: Efficacy of the RAF/PI3Kα/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600Ecolorectal tumor models." @default.
• W2022972276 doi "https://doi.org/10.1158/1538-7445.am2013-2337" @default.
• W2022972276 hasPublicationYear "2013" @default.
• W2022972276 type Work @default.
• W2022972276 sameAs 2022972276 @default.
• W2022972276 citedByCount "3" @default.
• W2022972276 countsByYear W20229722762017 @default.
• W2022972276 countsByYear W20229722762022 @default.
• W2022972276 countsByYear W20229722762023 @default.
• W2022972276 crossrefType "journal-article" @default.
• W2022972276 hasAuthorship W2022972276A5022308157 @default.
• W2022972276 hasAuthorship W2022972276A5025118565 @default.
• W2022972276 hasAuthorship W2022972276A5038165954 @default.
• W2022972276 hasAuthorship W2022972276A5043091366 @default.
• W2022972276 hasAuthorship W2022972276A5049772515 @default.
• W2022972276 hasAuthorship W2022972276A5082210211 @default.
• W2022972276 hasConcept C121608353 @default.
• W2022972276 hasConcept C126322002 @default.
• W2022972276 hasConcept C143998085 @default.
• W2022972276 hasConcept C150903083 @default.
• W2022972276 hasConcept C184235292 @default.
• W2022972276 hasConcept C185592680 @default.
• W2022972276 hasConcept C197934379 @default.
• W2022972276 hasConcept C207001950 @default.
• W2022972276 hasConcept C2776131300 @default.
• W2022972276 hasConcept C2777658100 @default.
• W2022972276 hasConcept C2778375690 @default.
• W2022972276 hasConcept C2778472372 @default.
• W2022972276 hasConcept C2778830669 @default.
• W2022972276 hasConcept C2779998722 @default.
• W2022972276 hasConcept C2994587330 @default.
• W2022972276 hasConcept C502942594 @default.
• W2022972276 hasConcept C526805850 @default.
• W2022972276 hasConcept C55493867 @default.
• W2022972276 hasConcept C57074206 @default.
• W2022972276 hasConcept C71924100 @default.
• W2022972276 hasConcept C86803240 @default.
• W2022972276 hasConcept C98274493 @default.
• W2022972276 hasConceptScore W2022972276C121608353 @default.
• W2022972276 hasConceptScore W2022972276C126322002 @default.
• W2022972276 hasConceptScore W2022972276C143998085 @default.
• W2022972276 hasConceptScore W2022972276C150903083 @default.
• W2022972276 hasConceptScore W2022972276C184235292 @default.
• W2022972276 hasConceptScore W2022972276C185592680 @default.
• W2022972276 hasConceptScore W2022972276C197934379 @default.
• W2022972276 hasConceptScore W2022972276C207001950 @default.
• W2022972276 hasConceptScore W2022972276C2776131300 @default.
• W2022972276 hasConceptScore W2022972276C2777658100 @default.
• W2022972276 hasConceptScore W2022972276C2778375690 @default.
• W2022972276 hasConceptScore W2022972276C2778472372 @default.
• W2022972276 hasConceptScore W2022972276C2778830669 @default.
• W2022972276 hasConceptScore W2022972276C2779998722 @default.
• W2022972276 hasConceptScore W2022972276C2994587330 @default.
• W2022972276 hasConceptScore W2022972276C502942594 @default.
• W2022972276 hasConceptScore W2022972276C526805850 @default.
• W2022972276 hasConceptScore W2022972276C55493867 @default.
• W2022972276 hasConceptScore W2022972276C57074206 @default.
• W2022972276 hasConceptScore W2022972276C71924100 @default.
• W2022972276 hasConceptScore W2022972276C86803240 @default.
• W2022972276 hasConceptScore W2022972276C98274493 @default.
• W2022972276 hasIssue "8_Supplement" @default.
• W2022972276 hasLocation W20229722761 @default.
• W2022972276 hasOpenAccess W2022972276 @default.
• W2022972276 hasPrimaryLocation W20229722761 @default.
• W2022972276 hasRelatedWork W1868879889 @default.
• W2022972276 hasRelatedWork W1984899592 @default.
• W2022972276 hasRelatedWork W2029761866 @default.
• W2022972276 hasRelatedWork W2142913791 @default.
• W2022972276 hasRelatedWork W2563532854 @default.
• W2022972276 hasRelatedWork W2617846385 @default.
• W2022972276 hasRelatedWork W2808608845 @default.
• W2022972276 hasRelatedWork W2885848575 @default.
• W2022972276 hasRelatedWork W3201934781 @default.
• W2022972276 hasRelatedWork W4246006194 @default.
• W2022972276 hasVolume "73" @default.
• W2022972276 isParatext "false" @default.
• W2022972276 isRetracted "false" @default.
• W2022972276 magId "2022972276" @default.
• W2022972276 workType "article" @default.